A randomized, double-blind, placebo-controlled, parallel-group, multicenter study comparing an eight-week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual initiation date (Nov 2005) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 01 Dec 2009 Results reported in Clinical Therapeutics.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History